NASDAQ: SUPN

Price:
8.97
Change:
+ 0.38
Day High:
9.04
Day Low:
8.49
Volume:
383,500
3:21 PM ET on Aug 22, 2014
Delayed at least 20 minutes.
Provided by eSignal.

Shareholder Tools

Press Releases

Search Press Releases

Keyword(s):

All Releases
View Summary Supernus Announces Paragraph IV ANDA Filing for Trokendi XR(R)
Aug 21, 2014
PDF 16.0 KB Add to Briefcase
View Summary Supernus to Attend FBR HealthCare Conference in September
Aug 19, 2014
PDF 14.6 KB Add to Briefcase
View Summary Supernus Receives FDA Fast Track Designation for SPN-810
Aug 14, 2014
PDF 17.5 KB Add to Briefcase
View Summary Supernus Announces Second Quarter 2014 Results
Aug 11, 2014
PDF 263.9 KB Add to Briefcase
View Summary Supernus to Host Second Quarter 2014 Earnings Conference Call
Jul 29, 2014
PDF 15.5 KB Add to Briefcase
View Summary Supernus to Receive $30 Million in Non-Dilutive Royalty Deal
Jul 8, 2014
PDF 83.9 KB Add to Briefcase
View Summary Supernus to Present at Jefferies Healthcare Conference in June
May 21, 2014
PDF 18.1 KB Add to Briefcase
View Summary Supernus Receives $2 Million Milestone for United Therapeutics' Launch of Orenitram(TM)
May 20, 2014
PDF 17.7 KB Add to Briefcase
View Summary Supernus Announces First Quarter 2014 Results
May 12, 2014
PDF 29.1 KB Add to Briefcase
View Summary Supernus to Host First Quarter 2014 Earnings Conference Call
Apr 29, 2014
PDF 15.3 KB Add to Briefcase
View Summary Supernus Announces Fourth Quarter and Full Year 2013 Results
Mar 12, 2014
PDF 30.9 KB Add to Briefcase
View Summary Supernus Announces Issuance of Third US Patent Protecting Trokendi XR™
Mar 12, 2014
PDF 11.8 KB Add to Briefcase
View Summary Supernus to Host Fourth Quarter and Full Year 2013 Earnings Conference Call
Feb 25, 2014
PDF 10.3 KB Add to Briefcase
View Summary Supernus to Present at Cowen and Company Healthcare Conference in March
Feb 20, 2014
PDF 9.3 KB Add to Briefcase
View Summary Supernus at Citibank and RBC Global Healthcare Conferences in February
Feb 7, 2014
PDF 9.3 KB Add to Briefcase
View Summary Supernus Announces Publication of Phase III Study (PROSPER) Results on Oxtellar XR®
Feb 3, 2014
PDF 58.4 KB Add to Briefcase
View Summary Supernus Announces Issuance of First Use Patents Protecting SPN-812 as a Novel Non-Stimulant ADHD Product
Jan 27, 2014
PDF 11.3 KB Add to Briefcase
View Summary Supernus Announces Issuance of Third US Patent Protecting Oxtellar XR(R)
Jan 7, 2014
PDF 10.3 KB Add to Briefcase
View Summary Supernus Announces Resignation of Board Member
Dec 24, 2013
PDF 8.7 KB Add to Briefcase
View Summary Supernus Announces FDA Approval of Its Partner's Product, Orenitram(TM)
Dec 23, 2013
PDF 10.4 KB Add to Briefcase
Showing 1-20 of 73 Page: 1 2 3 4  Next 20
Add to Briefcase = add release to Briefcase

This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, those statements regarding the company's future financial position, business strategy, budgets, projected costs, plans and objectives of management for future operations. Forward-looking statements contain uncertainties, and may turn out to be materially different. Please see the company's risk factors enumerated in its filings with the Securities and Exchange Commission.